C57BL/6-Pcsk9tm1(PCSK9)Bcgen/Bcgen • 110928
| Product name | B-hPCSK9 mice |
|---|---|
| Catalog number | 110928 |
| Strain name | C57BL/6-Pcsk9tm1(PCSK9)Bcgen/Bcgen |
| Strain background | C57BL/6 |
| NCBI gene ID | 100102 |
| Aliases | proprotein convertase subtilisin/kexin type 9, FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1, PC9 |
on this page
mRNA expression analysis
Strain specific analysis of PCSK9 gene expression in wild-type mice and B-hPCSK9 mice by RT-PCR. Mouse Pcsk9 mRNA was detectable in liver of wild-type mice (+/+). Human PCSK9 mRNA was detectable only in homozygous B-hPCSK9 but not in wild-type mice.
Protein expression analysis
Analysis of lipid metabolism after PCSK9 humanization in B-hPCSK9 mice
Lipid metabolism analysis in B-hPCSK9 mice. Plasma concentrations of TG, TC, LDL-C, and HDL-C in B-hPCSK9 mice and wild-type C57BL/6 mice (n = 36, 6 weeks) were analyzed. There is no difference between B-hPCSK9 mice and wild-type C57BL/6 mice.TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
In vivo efficacy of anti-human PCSK9 antibody with WD-induced B-hPCSK mice
In vivo efficacy of anti-human PCSK9 antibody with WD-induced B-hPCSK9 mice
Anti-human PCSK9 antibody upregulated LDLR levels in male B-hPCSK9 mice. B-hPCSK9 mice were treated with Alirocumab (in house)/Evolocumab(in house) or isotype control antibody(single dose, s.c.) (n = 6). Liver tissues were collected on Day 8 for ELISA analysis. LDLR levels were upregulated in the anti-human PCSK9 antibody-treated male mice group compared to the isotype control. Values are expressed as mean ± SEM. LDLR, low-density lipoprotein cholesterol receptor. WD, the Western diet.
